Jasper's IgAN readout nears as small-cap biotechs fund through deals and sales
Jasper has completed IgAN cohort enrolment, closed its Kira deal and reports $135.3M in cash. Its Q4 interim readout lands as buyers pick up small and mid-cap assets.
What happened
Jasper Therapeutics (JSPR) used its Q3 2026 update to report three things: it has completed enrolment of the IgA nephropathy (IgAN) cohort in its Phase 2 renal basket study of vensobafusp alfa, the Kira deal has closed, and cash stands at $135.3M. Interim IgAN data are expected in the fourth quarter.
The sequence matters. Enrolment is complete, so the readout is now a matter of timing rather than recruitment risk. The balance sheet is stated at a specific figure as the transaction closes. The material provided does not give the terms of the Kira transaction, so we do not characterise its economics or what Jasper gave or received.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on CompePharma and VigiEye
- One subscription for both sites, cancel any time
Sources
- Jasper Therapeutics completes IgAN cohort enrolment as Kira deal closes and cash reaches $135.3M Jasper Therapeutics, Inc. · 16 Nov 2026
- Viatris completes $36.50-a-share cash acquisition of Pacira BioSciences after tender offer Viatris Inc · 17 Nov 2026
- UL Solutions to acquire supply chain software firm Worldly in roughly $350M deal UL Solutions Inc. · 17 Nov 2026
- Gedeon Richter to acquire Mayne Pharma in AUD 604 million cash deal Gedeon Richter · 16 Nov 2026
- Aytu BioPharma to be acquired by Rosemont for about $56M as EXXUA sales grow Aytu Biopharma, Inc · 16 Nov 2026
Written by CompePharma's editorial system (AI-assisted, model claude-sonnet-5-5) strictly from the official material listed. It can contain errors; check the sources. Not investment advice.
Retension's $51.75M IPO buys a Phase 2b readout, but trial costs will set the clock
Retension's first earnings report since its upsized October IPO shows a $5.9M quarterly loss and a single catalyst: RTN-001 Phase 2b data in H1 2027. Peers show how thin other routes to capital are.
Insight Molecular's $15M raise shows how thin the small-cap diagnostics funding market is
IMDX's $1.75-per-share offering, with pre-funded warrants and a transplantation R&D pitch, sits at the small end of a financing spectrum that runs from a $51.75M IPO to royalty sales.
Kyntra's prostate exit shows how thin the funding runway is for a biotech that has to reset
After a Phase 2 interim miss, Kyntra Bio is cutting its royalty-financing cap and pivoting to roxadustat in MDS, and its plan is subject to funding in a split biotech capital market.